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ABSTRACT 
The high drug loading and excellent biocompatibilities of metal-organic frameworks (MOFs) 
have led to their application as drug delivery systems (DDSs). Nanoparticle surface 
chemistry dominates both biostability and dispersion of DDSs while governing their 
interactions with biological systems, cellular and/or tissue targeting, and cellular 
internalisation, leading to a requirement for versatile and reproducible surface 
functionalisation protocols. Herein, we explore not only the effect of introducing different 
surface functionality to the biocompatible Zr-MOF UiO-66, but also the efficacy of three 
surface modification protocols: (i) direct attachment of biomolecules (folic acid, biotin) 
introduced as modulators of UiO-66 synthetic, (ii) our previously reported ‘’click-modulation” 
approach to covalently attach polymers (poly(ethylene glycol), poly-L-lactide, poly-N-
isopropylacrylamide) to the surface of UiO-66 through click chemistry, and (iii) surface ligand 
exchange, to postsynthetically coordinate folic acid, biotin and heparin to UiO-66. The 
innovative use of a small molecule with metabolic anticancer activity, dichloroacetic acid 
(DCA), as a modulator during synthesis is described, and found to be compatible with all 
three protocols, yielding surface-coated, DCA-loaded (10-20% w/w) nanoMOFs (70-170 
nm). 
External surface modification generally enhances stability and colloidal dispersion of UiO-66. 
Cellular internalisation routes and efficiencies of UiO-66 by HeLa cervical cancer cells can 
be tuned by surface chemistry, and anticancer cytotoxicity of DCA-loaded MOFs correlates 
with endocytosis efficiency and mechanisms. The MOFs with the most promising coatings 
(folic acid, poly(ethylene glycol), poly-L-lactide, and poly-N-isopropylacrylamide) were 
extensively tested for selectivity of anticancer cytotoxicity against MCF-7 breast cancer cells 
and HEK293 healthy kidney cells, as well as for cell proliferation and ROS production 
against J774 macrophages and peripheral blood lymphocytes (PBLs) isolated from the blood 
of human donors. DCA-loaded, folic acid modified UiO-66 selectively kills cancer cells 
without harming healthy ones or provoking immune system response in vitro, suggesting a 
significant targeting effect and great potential in anticancer drug delivery. The results provide 
mechanistic insight into the design and functionalisation of MOFs for drug delivery, and 
underline the availability of various in vitro techniques to potentially minimise early-stage in 
vivo animal studies, following the three Rs: reduction, refinement and replacement.  
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INTRODUCTION 
Drug delivery systems (DDSs) have become an exciting alternative to conventional 
treatments for many diseases, such as cancer, as they have the potential to reduce 
unwanted side effects while maximizing treatment efficiency.1 Several strategies have been 
studied, but the application of DDSs is often limited by bioavailability,2 uncontrolled release 
of the drug (i.e. the burst effect),3 poor loading capacity,4 toxicity5 and inefficient cellular 
internalisation.6 Among them, metal-organic frameworks (MOFs)7 – hybrid, highly porous 
crystalline structures composed of metal clusters linked by multidentate organic ligands – 
offer several advantages compared to available DDSs, as they combine desirable features 
of both organic (biocompatibility) and inorganic (high loadings) systems.8-10  
Surface modifications of DDSs can minimize their interaction with the bulk, improving 
stability and dispersion,11 and allowing them to cross physiological barriers,12 providing the 
possibility of targeted carriers.13 They can also decrease immune system recognition.10,14 
Despite the clear need to develop reproducible and versatile protocols to modify the outer 
surfaces of MOFs, few studies have addressed this issue so far, and even though it has 
been reported that drugs can be introduced into MOFs during synthesis,15 achieving one pot-
syntheses to create drug containing nanoparticulate MOFs (NMOFs) with functionalised 
surface is still a challenging goal. Different approaches to functionalise the surfaces of MOFs 
have been reported,16 which can be categorised into functionalisation during synthesis, by 
using the coordination modulation approach,17 or through postsynthetic modification.18-20  
The Lewis acid character of MOFs’ metal centres offers the possibility of coordinating 
nucleophiles to the coordinatively unsaturated metal sites available on the outer surface of 
NMOFs. In order to avoid inner surface functionalisation, this postsynthetic modification is 
usually achieved through size-selective protocols, where the functionality cannot penetrate 
the porosity. This approach was first reported by Rowe et al.,18 and since then has been 
applied by different groups. For example, histidine residues (his-tags), which contain 
imidazole groups, have been used to coordinate several peptides and proteins to three 
different MOFs surfaces: to the copper benzenetricarboxylate MOF, HKUST-1; to the iron-
fumarate MOF MIL-88A and to a related zirconium fumarate MOF.19 Additionally, several 
polymer coatings, including oligonucleotides, have been added to the surfaces of MOFs by 
coordination to the metal clusters through one of the polymers’ ends.21-23 The well-known 
surface ligand exchange (SLE) protocol – postsynthetically exchanging surface ligands for 
desired functionality – is also based on coordination chemistry.24  
It is also important to mention that silica coating has been widely used to increase MOFs’ 
water stability, induce slow release, and to attach surface reagents through the siloxane 
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groups.25 Although this approach can dramatically enhance some MOFs properties, 
drawbacks exist in the fact that the silica coating can block pore access, and that some silica 
nanoparticles have been found to be toxic.26 
Postsynthetic covalent modifications, performed on functionalised organic linkers, have been 
widely used in biological applications of NMOFs.27 For example, Lin and co-workers 
postsynthetically attached a cisplatin prodrug to MIL-101-NH2 amino group present in the 
MOF linker28 They also utilised a cisplatin prodrug as the linker directly during synthesis,25 
followed by silica coating and subsequent targeting peptide attachment. Once again, to 
selectively functionalise the outer surface, a surface reagent bigger than the pore opening is 
required. Additionally, unsaturated carboxylic acid groups present on the MOF surface can 
also be exploited for postsynthetic covalent surface modifications. For example, a green 
fluorescent protein was coupled to surface carboxylate groups of different MOFs using a 
carbodiimide-mediated reaction,29 and then the protocol was applied to couple PEG5000-
NH2 and Stp-10C,
20 a derived oligoamino amide with proton-sponge features. However, the 
low reactivity of the organic linker’s carboxylates hinders the application of this protocol, 
resulting in very low surface coatings (1-2% w/w).  
Interest in zirconium-based MOFs as DDSs is arising as a consequence of their high 
chemical stability compared to iron MOFs,30 and their safe use has been validated in 
vitro12,23,31-39 and in vivo,40 showing almost no acute cytotoxicity, with efficient performance in 
anticancer drug delivery. In particular, the zirconium terephthalate MOF UiO-66 (UiO 
standing for Universitetet i Oslo) has excellent biocompatibility40 which, together with its well-
known structure and characterisation,41 ability to cross the cell membrane33,36 and pH 
responsive drug release,35,36 makes it a great candidate for nanoparticle-conjugated 
anticancer drug delivery. Additionally, it is well known that monocarboxylic acid 
functionalised modulators can be attached to its surface and defect sites during synthesis, 
yielding highly porous nanoparticles.42  
We have previously reported the ‘’click modulation’’ protocol for UiO-66,32 in which we 
introduced functionalised modulators (p-azidomethylbenzoic acid, L1 and p-
propargyloxybenzoic acid, L2, Fig 1) to UiO-66 nanoparticle surfaces and defect sites during 
their synthetic process, followed by postsynthetic covalent conjugation of different surface 
functionality using copper(I)-catalysed azide-alkyne cycloaddition (CuAAC). Attaching 
protecting PEG2000 chains to the MOF surface enhanced stability in phosphate buffered 
saline (PBS) solutions, enabled pH-responsive cargo release and tuned UiO-66 cell uptake 
pathways from clathrin-mediated to the more desirable caveolae-mediated route, which 
allows particles to circumvent cargo degradation in the lysosomes.36 The effect of surface 
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chemistry on DDS efficiency was evident in the enhanced cytotoxicity of the anticancer drug, 
dichloroacetate (DCA), which can be loaded into the NMOF as a co-modulator 
(dichloroacetic acid) during synthesis. Only the PEGylated MOF enhanced the cytotoxicity of 
DCA towards HeLa cancer cells, likely as NMOFs internalised through caveolae-mediated 
endocytosis can escape the early endosome, resulting in cytosolic release of the cytotoxic 
cargo.  
 
Figure 1. Schematic showing our “click modulation” surface functionalisation protocol for UiO-66 
using the functionalised modulators L1 and L2.
32
 Note that in this study, UiO-66-L2 is prepared by 
surface ligand exchange from UiO-66-L1, and not through coordination modulation.  
The need to find a rationalisation between the intrinsic characteristics of NMOFs, such as 
surface chemistry, and their therapeutic efficacy is inherently clear, providing if so the 
possibility of reducing animal testing while maximizing the potential application of MOFs as 
DDSs. Thus, we chose to further explore the different ways of functionalising the outer 
surface of UiO-66 nanoparticles, in order to characterise the effect of surface modifications 
on properties such as physiological stability and colloidal dispersion. Then, through 
thoughtful choice of surface reagents with different characteristics – hydrophilic or 
hydrophobic, targeting agents, negatively charged, positively charged or neutral – we 
attempt to rationalise the effect of surface chemistry of UiO-66 on HeLa cell internalisation 
pathways, therapeutic efficiency, selectivity of cytotoxicity (targeting) and in vitro immune 
response.  
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RESULTS AND DISCUSSION  
Three different surface modification protocols were assessed: (i) direct incorporation of 
functionality through coordination modulation (CM), (ii) postsynthetic surface ligand 
exchange (PS), and (iii) click modulation, wherein functionalised modulators are covalently 
modified (Figure 2a). Different surface reagents (Figure 2b) which possess various 
coordinating groups – vitamin B9 folic acid (FA), vitamin B7 biotin (Biot), and a negatively 
charged anticoagulant, heparin (Hep) – that are well known to play different biological roles 
in targeting and binding, were selected to be potentially coordinated to UiO-66 surfaces 
postsynthetically. The carboxylic acid functionalities of both folic acid and biotin allowed their 
direct incorporation during modulated syntheses. Additionally, the hydrophobic propargyl-
terminated poly-L-lactide (PolyLact, Mn = 2000) and the hydrophilic azide-terminated poly-N-
isopropylacrylamide (PNIPAM, Mn = 15000)
43 were selected as protecting polymers to click 
to UiO-66-L1 and UiO-66-L2 surface. Thus, we have evaluated the properties that different 
surface coatings provide to UiO-66 and the potential and reproducibility of different protocols 
to introduce different functionalities.  
 
Figure 2. a) Synthetic scheme for the surface modified MOFs, highlighting 8 MOFs obtained through 
coordination modulation (CM), postsynthetic exchange (PS) and click modulation. b) Chemical 
structures of the surface functionality attached to the MOFs. 
 
 
Synthesis and Characterisation 
Coordination Modulation: UiO-66-L1 was synthesised (see Figure 2a for synthetic 
methodologies) following our previously reported coordination modulation solvothermal 
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protocol.32 The coordination modulation approach, first reported by Fisher and co-workers,44 
is based on the use of modulators with similar chemical functionality to the linker during the 
synthetic process. However, the modulators can play different roles during synthesis, in 
some occasions inducing defects (such as missing linkers or clusters)42 as well as capping 
crystal surfaces. This approach can also be used for size control45 through coordination to 
the metal units (if acting as a capping agent) or through promotion of crystal growth. After 
successful synthesis of UiO-66-L1, L1 was replaced by L2 through surface ligand exchange, 
yielding UiO-66-L2, in order to maintain constant particle size. Full characterisation of both 
materials (SI, Section S3.1) showed highly crystalline nanoparticles, as confirmed by powder 
X-ray diffraction (PXRD), with the appropriate size for drug delivery, ca. 150 nm, determined 
by scanning electron microscopy (SEM), and high modulator content, determined by 1H 
NMR spectroscopy (15-27 mol % compared to bdc). N2 adsorption isotherms confirmed that 
L1 and L2 are attached to UiO-66 external surface and defect sites: SBET = 1591 m
2g-1 (UiO-
66-L1) and 1349 m2g-1 (UiO-66-L2) are higher than pristine UiO-66, typically 1200 m2g-1.41 
These results show that L1 can be easily exchanged by L2 – and thus potentially other 
coordinating agents – postsynthetically on the outer surface of UiO-66-L1.  
We subsequently used both folic acid and biotin as modulators in solvothermal syntheses of 
UiO-66 (SI, Section S3.2). The samples were named UiO-66-FA (CM) and UiO-66-Biot-
AcOH (CM) to reflect that acetic acid was required as a co-modulator in the synthesis of the 
biotin-coated sample, where CM stands for coordination modulation to distinguish them from 
samples prepared by postsynthetic ligand exchange (Figure 2a). The samples were 
crystalline and phase pure as confirmed by PXRD (Figure 3a). 1H NMR spectra of acid 
digested samples of the NMOFs showed the presence of the functional modulator in both 
cases (28 mol % for folate and only 2 mol % for biotin, see Table 1), but no AcOH in UiO-66-
Biot-AcOH (CM). The gravimetric folic acid content was also calculated by UV-Vis 
spectroscopy of acid digested UiO-66-FA (CM), and found to be 13.6% (w/w)  
Fourier transform infra-red (FT-IR) spectra showed appearance of modulator signals with 
slight shifts as a possible consequence of their coordination to the available zirconium units. 
In concordance, thermogravimetric analysis (TGA) profiles showed new mass loss events 
starting at higher temperatures than the free modulators’ thermal decomposition, strongly 
indicating their attachment, which was unequivocally confirmed by nitrogen adsorption and 
desorption isotherms, revealing highly porous samples. UiO-66-Biot-AcOH (CM) was more 
porous – with a BET area of 1377 m2g-1 – than UiO-66-FA (CM), which exhibited a BET area 
of 753 m2g-1. This could be explained by the higher modulator content in UiO-66-FA (CM) 
and the likely poorer crystallinity and/or smaller particle size indicated by the broad Bragg 
peaks in the PXRD pattern. SEM (Figure 3b) showed UiO-66-FA (CM) to have a 
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homogeneous distribution of small nanoparticles (~50 nm), reflected in the broadening of its 
PXRD pattern, and indicating that folic acid is acting as a capping agent during UiO-66 
synthesis. On the other hand, UiO-66-Biot-AcOH (CM) forms as well-defined nanoparticles 
around 150 nm in size. 
 
Figure 3. a) Stacked PXRD patterns of the surface modified UiO-66 samples. SEM images of b) UiO-
66-FA (CM), showing a very small particle size consistent with the broad PXRD, c) UiO-66-L2-
PNIPAM, showing a rounded morphology due to polymer coating, d) UiO-66-Biot (PS), and e) UiO-
66-Biot-AcOH (CM), showing the differences in particle size and morphology from different surface 
modification techniques. 
These results confirm that coordination modulation can be used to simultaneously control 
the surface chemistry and particle size of NMOFs. It has been previously reported that when 
the modulator is the only parameter varied during synthesis, particle size strongly correlates 
with the pKa of the modulator.
45 Our results also suggest that pKa influences modulator’s 
attachment; the pKa values of the carboxylic acids of bdc are 3.54 and 4.46, while folic acid 
has pKa values of 3.5 and 4.3, biotin has a pKa of 4.5, and AcOH a pKa of 4.8, and therefore 
folic acid attachment is higher than biotin, while AcOH is not incorporated. Further, folic acid 
has two carboxylic acids in its structure while biotin has only one, and it has been reported 
that when coordinating histidine-conjugated peptides to a Zr-fumarate MOF, the binding 
affinity increases with the number of histidine residues.19  
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Table 1. Characterisation data for the surface-modified MOFs. 
Sample 
BET area 
(m2g-1) 
SEM Particle 
size (nm) 
Estimated surface coating 
1H NMR 
(mol %)a 
TGA 
(% w/w)b 
UV-Vis 
(% w/w)c 
UiO-66-L1 1591 143 ± 31 15 n/a n/a 
UiO-66-L2 1349 142 ± 14 27 n/a n/a 
UiO-66-L1-PolyLact 1129 177 ± 25 n/a 10 n/a 
UiO-66-L2-PNIPAM 1030 177 ± 24 n/a 3 n/a 
UiO-66-FA (PS) 879 168 ± 26 40 25 23.6 
UiO-66-Biot (PS) 949 175 ± 17 10 12 n/a 
UiO-66-Hep (PS) 891 157 ± 34 n/a 27 n/a 
UiO-66-FA (CM) 753 36 ± 13 28 13 13.6 
UiO-66-Biot-AcOH (CM) 1227 157 ± 16 2 4 n/a 
a
Values could not be measured for polymeric samples as integral ratios could not be accurately 
compared. 
b
Values derived by TGA analysis are complicated by additional overlapping mass loss 
events and so should be considered estimates. 
c
Only folic acid content can be determined by UV/Vis 
spectroscopy.  
Surface Ligand Exchange: Postsynthetic coordination of folic acid, biotin and heparin to 
the surface of UiO-66-L1 was carried out, and the samples were named UiO-66-FA (PS), 
UiO-66-Biot (PS) and UiO-66-Hep (PS), where PS stands for postsynthetic (SI, Section 3.1). 
As a consequence of surface ligand exchange, D2SO4/d6-DMSO acid-digested 
1H NMR 
spectra of the functionalised NMOFs showed disappearance of resonances for protons of L1 
and appearance of resonances assigned to folic acid, biotin and heparin. FT-IR spectra of 
the MOFs showed the disappearance of the azide band of L1 and the appearance of new 
vibration bands characteristic of the surface reagents, some of them slightly shifted, possibly 
as a consequence of coordination. TGA profiles of the functionalised samples showed new 
mass loss events, starting at a higher temperature than authentic samples of the 
coordinating agents, strongly suggesting attachment by coordination rather than simply 
surface adhesion. The metal residue (ZrO2) at 800 °C was considerably lower than for their 
precursor sample UiO-66-L1, suggesting significant organic mass addition at the surfaces. 
The fact that the samples retained porosity – with BET areas between 870 and 950 m2g-1 – 
confirmed attachment to UiO-66 external surface without blocking the pores, although the 
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slightly lower gravimetric surface areas are likely a consequence of the additional mass of 
the surface functionality. 
Click Modulation: Propargyl-terminated poly-L-lactide and azide-terminated poly-N-
isopropylacrylamide were attached to UiO-66-L1 and UiO-66-L2 respectively by CuAAC 
“click” chemistry using our previously reported click-modulation protocol,32 yielding UiO-66-
L1-Poly-L-Lact and UiO-66-L2-PNIPAM nanoparticles (SI, Section 3.1). In a similar manner 
to our previously reported UiO-66-L1-PEG2000, the samples were fully characterised by 
TGA, FT-IR spectroscopy and N2 adsorption isotherms, confirming the reproducibility of the 
click modulation protocol to covalently conjugate various polymers to UiO-66 outer surfaces. 
The TGA profile of UiO-66-L1-PolyLact showed new mass loss events (10% w/w) at a higher 
temperature than propargyl-terminated poly-L-lactide due to its covalent attachment. Similar 
features were observed in the TGA profile of UiO-66-L2-PNIPAM, for which we estimate a 
3% (w/w) of PNIPAM present in the structure. The thermal stabilities of both functionalised 
NMOFs slightly decreased as a consequence of the thermal decomposition of the polymers 
anchored to their surface. Control samples, in which polymers were stirred with 
functionalised NMOFs without the presence of the Cu(I) catalyst, showed no new thermal 
decomposition steps or decrease in thermal stability, further indicating covalent attachment 
of the polymers using the CuAAC protocol. The physical changes to the surface 
functionalised NMOFs’ morphologies were examined by SEM (Figure 3b), revealing a more 
rounded shape after surface coating compared to octahedral UiO-66-L1 nanoparticles, with 
the slight increase in particle size a consequence of the surface coating. 
Stability and Dispersion of Surface Modified UiO-66 
Our previous study showed that PEGylation enhanced the dispersion of UiO-66 in various 
solvents; unwanted aggregation could hinder cellular uptake and induce in vivo toxicity of 
DDSs.32 The solution stability and aggregation of the surface-modified NMOFs were 
investigated through dynamic light scattering (DLS) measurements of samples dispersed 
(0.25 mgml-1) in methanol, water and PBS (SI, Section S4). The postsynthetically 
functionalised samples were all derived from the same batch of UiO-66-L1, measured to be 
around 150 nm in size by SEM, allowing close comparison. In methanol, the highly charged 
heparin-coated UiO-66-Hep showed the greatest aggregation (ca. 700 nm) compared to 
UiO-66-L1 (ca. 300 nm), while the other samples showed less aggregation, particularly the 
polymer-modified UiO-66-L1-PolyLact and UiO-66-L2-PNIPAM samples (200-250 nm). 
Significant aggregation and precipitation of UiO-66-L1 and UiO-66-L2 were observed in 
water, and UiO-66-FA (PS) also formed significant aggregates (ca. 700 nm). UiO-66-Biot 
(PS) and UiO-66-L1-PolyLact showed a small degree of aggregation (ca. 400 nm) whilst 
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UiO-66-L2-PNIPAM was initially monodisperse (ca. 150 nm) but aggregated over time, and 
UiO-66-Hep appeared to shed its surface coating and precipitate, clearly indicating the effect 
of external surface modification on colloidal stability.  
Measurements performed in PBS again showed aggregation and precipitation of UiO-66-L1 
and UiO-66-L2, while after surface coating, more stable dispersions were found (Figure 4a). 
UiO-66-FA (PS), UiO-66-Biot (PS) and UiO-66-Hep (PS) all showed less aggregation than 
the uncoated samples, with stable dispersions of approximately 600-1000 nm. The samples 
covalently functionalised through the ‘‘click modulation’’ approach, UiO-66-L1-PolyLact and 
UiO-66-L2-PNIPAM, again had enhanced dispersive stability, with initial measurements 
showing size distributions close to those determined by SEM followed by slightly aggregation 
to 400-700 nm during the course of the experiment.  
 
Figure 4. a) DLS measurements of the MOFs (0.25 mgml
-1
, PBS) showing the effect of surface 
functionality on aggregation. b) Degradation profiles (release of bdc ligand in PBS), showing that 
surface groups can slow down degradation by phosphate. 
Similar behaviour was observed for the samples functionalised through coordination 
modulation, UiO-66-FA (CM) and UiO-66-Biot-AcOH (CM), although the biotin-modified 
sample showed significant aggregation in PBS (ca. 1200 nm), possibly as a consequence of 
12 
 
its low (ca. 2 mol %) surface functionalisation. Overall, all the external surface modified 
samples showed enhanced dispersion in PBS compared to unmodified materials, with the 
extent of the improvement related to the size and charge of the surface functionality. It is 
important to note that while DLS measurements are performed without stirring, the blood 
current is a dynamic system. It has also been reported that while MOFs usually aggregate in 
PBS, the presence of proteins such as Bovine Serum Albumin (BSA), present in cells growth 
media and blood current, results in stable colloidal dispersions as a consequence of protein 
corona formation.46 While the lability of the metal-linker bonds at acidic pH values ensures 
decomposition of NMOFs in intracellular conditions, thus avoiding accumulation in the body, 
the coordinative nature of this bond can be a disadvantage as coordinating groups, such as 
phosphates, are able to displace the linkers in extracellular conditions resulting in 
undesirable fast-release kinetics. External surface coatings10 and approaches such as 
postsynthetic and post drug loading amorphisation33,35 or silica coating25 have been studied 
to overcome this problem. The stabilities of the externally surface coated NMOFs were 
determined in PBS (pH 7.4) by UV/Vis spectroscopic measurement of the release of the 
linker, bdc, and compared to the degradation profile of UiO-66-L1 (SI, Section S5). 
Additionally, the release of folic acid was determined for the corresponding two samples. 
The postsynthetically external surface modified samples exhibit induction times of different 
lengths (1-4 h) depending on the sample, for which the degradation rates were considerably 
slower than UiO-66-L1 (Figure 4b). Interestingly, after 2.5 h, the degradation of UiO-66-Hep 
(PS) is higher than UiO-66-L1, showing that depending of the nature of the coating – in this 
case hydrophilic and highly soluble in water – the degradation rate can be also increased 
over certain timescales, if desired, by external surface modifications. In all the other cases, 
improvements in stability were found. Specifically, the UiO-66-L1 degradation profile (55% 
bdc release after 1 h) was tuned from exponential to sigmoidal in the case of UiO-66-L1-
PolyLact (27% bdc release after 1 h) and UiO-66-L2-PNIPAM (30% release after 1 h). The 
effect of different functionalisation techniques (coordination modulation or postsynthetic) is 
apparent when analysing the degradation profiles of the biotin and folic acid modified 
samples. Although in all cases stability towards phosphates was clearly enhanced, UiO-66-
FA (PS) and UiO-66-Biot (PS) exhibit a more pronounced induction time, with minor release 
during the first 30 minutes – both ~10% release versus 30% for UiO-66-L1, 15% for UiO-66-
Biot-AcOH (CM) and 20% for UiO-66-FA (CM) – possibly due to a higher degree of pore 
blockage hindering phosphate attack at the first stages. However, after 1 h in the case of the 
biotin containing samples, and 4 h in the case of the folate containing samples, the 
percentage of bdc released is higher for the postsynthetically modified samples. These 
results are mirrored in the release of folate from the external surface of the MOFs. 
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Endocytosis Efficiencies and Routes of Surface-Modified UiO-66 
Calcein was selected as a fluorescent molecule to track the NMOFs inside cells, in order to 
study endocytosis pathways.33 Calcein’s hydrophilicity does not allow it to efficiently cross 
the cell membrane, and thus intracellular cytoplasmic fluorescence is significantly increased 
when calcein is incorporated into a carrier.36 UiO-66-L1 and UiO-66-L2 were 
postsynthetically loaded with calcein following previously reported protocols, and their 
surfaces subsequently modified either using our click modulation method32 or postsynthetic 
external surface ligand exchange (PS) (Scheme 1), ensuring all samples were of similar 
particle size as they originated from one batch of UiO-66-L1. 
 
Scheme 1. Synthesis of calcein-loaded, surface modified MOFs obtained through postsynthetic 
exchange (PS) and click modulation. 
cal@UiO-66-L1-PolyLact and cal@UiO-66-L2-PNIPAM were prepared through CuAAC 
mediated conjugation of the surface polymers, while cal@UiO-66-FA (PS), cal@UiO-66-Biot 
(PS), cal@UiO-66-Hep (PS) were prepared by external surface ligand exchange from 
cal@UiO-66-L1 to introduce the external surface moieties (SI, Section S6.1). As previously, 
full characterisation confirmed the surface moieties’ attachment to the calcein-loaded 
NMOFs’ surface, and calcein loading was measured by UV/Vis spectroscopy of digested 
samples (Table 2). 
Table 2. Calcein loadings of the surface modified MOFs, determined by UV-Vis spectroscopy, and 
their subsequent endocytosis efficiencies for HeLa cells normalised to cal@UiO-66-L1. 
Sample 
Calcein Loading 
(UV-Vis, % w/w) 
Endocytosis 
Efficiency % 
cal@UiO-66-L1 17.9 100 
cal@UiO-66-L1-PolyLact 6.9 141 ± 2 
cal@UiO-66-L2-PNIPAM 8.0 150 ± 1 
cal@UiO-66-FA (PS) 9.8 184 ± 2 
cal@UiO-66-Hep (PS) 13.0 171 ± 3 
cal@UiO-66-Biot (PS) 12.8 37 ± 1 
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Fluorescence-activated cell sorting (FACS) was used to study the endocytosis efficiencies 
and pathways of the calcein-loaded, external surface modified NMOFs when incubated with 
HeLa cervical cancer cells (SI, Section S6.2). As all the cal@NMOF samples were prepared 
from the same base batch, we assume that variations are caused by changes in external 
surface chemistry, not particle size, in concert with our previous work which shows particle 
size has only minor effect until sizes >500 nm are reached.34 Uptake efficiency was analysed 
after incubating cells with a fixed NMOF concentration (0.5 mgmL-1), normalising the data to 
UiO-66-L1 cell internalisation, taking into account differing calcein loading values (Figure 
5a).  
 
Figure 5. a) Endocytosis efficiencies of the calcein-loaded MOFs compared to calcein alone. b) 
Endocytosis efficiency of the calcein-loaded MOFs when incubated with various inhibitors. The Key 
from part a) applies in part b). The statistical significance was determined by ordinary one-way 
ANOVA and is indicated on the part b): * = P≤ 0.05 ** = P≤ 0.01 *** = P≤ 0.001 **** = P≤ 0.0001. 
In general, cal@UiO-66 uptake is highly efficient compared to free calcein (6-10 fold 
increase), proving the validity of NMOFs as carriers to internalise cargo not able to efficiently 
cross the cell membrane by themselves. cal@UiO-66-Biot (PS) was, however, poorly 
internalised by HeLa cells compared to cal@UiO-66-L1, with the value of 37 ± 1% showing 
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that biotin coating might not be desirable to enhance NMOF cell internalisation. cal@UiO-66-
FA (PS) had the highest internalisation, followed by cal@UiO-66-Hep (PS), cal@UiO-66-L2-
PNIPAM, and cal@UiO-66-L1-Poly-Lact (Table 2). HeLa cells are known to over express the 
folate receptor (FR) on their surface,47 and therefore the folate present on the surface of 
cal@UiO-66-FA (PS) could bind to the FR, providing a mode of targeting and enhanced 
internalisation of the NMOF by cells expressing FR. 
To monitor the preferred routes of endocytosis, inhibitors were used to restrict uptake by 
certain pathways (SI, Section S6.3).36 Chlorpromazine and sucrose were used to inhibit 
clathrin-mediated pathways although it is important to consider that sucrose can additionally 
inhibit some non-mediated endocytosis processes. Nystatin was used as an inhibitor of 
caveolae-mediated endocytosis and rottlerin was used to inhibit macropinocytosis. Both 
unfunctionalised cal@UiO-6636 and cal@UiO-66-L132 have previously been shown to 
generally enter HeLa cells by clathrin-mediated endocytosis, while PEGylated cal@UiO-66-
L1-PEG2000 showed caveolae-mediated endocytosis,32 which is desirable for efficient 
treatment as the NMOF can potentially escape the early endosome, avoiding lysosome 
degradation and facilitating faster drug release in other cellular locations such as the 
cytosol.48 
When cells were incubated at 4 °C in order to decrease energy-dependent processes, such 
as endocytosis, cell internalisation of the NMOFs decreased by 50-85% compared to the 
control at 37° C (Figure 5b). The only exception was cal@UiO-66-Biot (PS), where cell 
internalisation only decreased by 28%, confirming the observations from the previous uptake 
experiments that it is not efficiently internalised by HeLa cells (SI, Figure S66). As no 
efficient internalisation is observed, no further experiments were carried out with this sample. 
Folate receptors have been reported to often be located within caveolae invaginations;47 
cal@UiO-66-FA (PS) uptake decreased to 62 ± 2% when HeLa cells were incubated with 
nystatin, a well-known caveolae-mediated endocytosis inhibitor, while no inhibition was 
found when incubated with chlorpromazine (clathrin-mediated inhibitor) (96 ± 3%), and only 
a minor effect (81 ± 5%) was observed when rottlerin was inhibiting macropinocytosis 
pathways. Sucrose significantly decreased cal@UiO-66-FA (PS) uptake to 36 ± 4%, 
meaning that folate coating not only provides a way of cancer targeting, but also alters 
cancer cell endocytosis selection pathways from clathrin-mediated to both caveolae-
mediated and non-mediated endocytosis. These results suggest that drug loaded UiO-66-FA 
samples have potential to be efficient therapeutic DDSs. Exposing HeLa cells to nystatin 
decreased cal@UiO-66-Hep (PS) cell internalisation to values of 60 ± 1%, showing that the 
heparin coated MOF is also partially internalised by caveolae-mediated endocytosis. 
However, in contrast to cal@UiO-66-FA (PS), clathrin-mediated routes also play a role in 
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HeLa cell internalisation of cal@UiO-66-Hep (PS), as normalised cell cytoplasmic 
fluorescence decreases to values of 70 ± 2%, while inhibiting macropinocytosis decreases 
the MOF normalised uptake to 83 ± 3%. Additionally, sucrose also decreased its cell 
internalisation to values of 41 ± 4%.  
In the cases of cal@UiO-66-L1-PolyLact and cal@UiO-66-L2-PNIPAM, cell internalisation 
decreased when inhibiting with sucrose (50 ± 5% and 54 ± 1%, respectively), while no 
significant decrease was found when inhibiting clathrin-mediated (84 ± 11% and 105 ± 5% 
respectively) or caveolae-mediated routes (106 ± 13% and 103 ± 4% respectively), and only 
minor macropinocytosis attributions upon PNIPAM coating (80 ± 4%). These results indicate 
that these polymer-coated samples are mainly internalised by non-mediated endocytosis 
processes, with a significant contribution for cal@UiO-66-L1-PolyLact from energy 
independent processes. 
Selectivity of Cytotoxicity of DCA-Loaded, Surface-Functionalised NMOFs 
We previously reported the validity of the coordination modulation protocol to introduce a 
small molecule with high metabolic anticancer activity, dichloroacetate (DCA),49,50 as a 
modulator that is attached to UiO-66 metal nodes during synthesis.32 DCA is a pyruvate 
dehydrogenase kinase (PDK) inhibitor which has been investigated for over 25 years for the 
treatment of mitochondrial disorders such as lactic acidosis.51 PDK is one of the main 
enzymes responsible for promoting glycolysis over glucose oxidation in cancer cells, as it 
can inhibit pyruvate dehydrogenase (PDH), an enzyme that converts pyruvate to 
acetylCoA.52 Once glucose has been transformed to pyruvate, instead of being 
decarboxylated to form acetylCoA and entering the Krebs cycle in the mitochondria, 
pyruvate is alternatively transformed to lactate in the cytosol of cancer cells,53 allowing them 
to grow in hypoxic conditions (low presence of oxygen) and resist apoptosis.54 DCA shifts 
cancer cells metabolism from glycolysis back to glucose oxidation by PDH re-activation, 
decreasing the mitochondrial membrane hyperpolarisation and activating Kv channels, thus 
unlocking cancer cells from a state of apoptosis resistance without affecting growth of 
healthy cells.49,50,55  
However, the hydrophilic nature of DCA means it does not efficiently cross the cell 
membrane56 and thus free DCA displays low cytotoxicity, with IC50 values in the milimolar 
range, three orders of magnitude lower than anticancer drugs such as cisplatin.57 DCA is 
rapidly cleared out from the blood stream, with initial half-life times of about an hour,58 
leading to poor efficacy and targeting when the drug is injected alone.55,57 Nevertheless, 
cancer cells have shown remarkably lower resistance factors to DCA compared to cisplatin 
and other anticancer therapeutics,57 which is a notable drawback for anticancer therapy.  
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Although DCA is not currently under clinical use as an anticancer drug, it has been studied 
as a potential metabolic cancer therapy since 2007,49 with several clinical trials showing 
significant tumour remission without healthy cells damage, low side effects and toxicity, and 
safe chronic use.59 However, due to its ability to cross the brain membrane barrier, chronic 
exposure to very high DCA doses can result in reversible peripheral neuropathy.51 
We have chosen DCA as the object of our study due to the fact that its cytotoxic effect will 
only be observed if MOFs are able to deliver cargo into the cytosol and subsequently reach 
the mitochondria. This allows experimental confirmation that therapeutically active DCA-
loaded MOF nanoparticles have been successfully internalised, and by specific endocytosis 
mechanisms that result in the DDS being localised in the cytosol rather than lysosomes. As 
such, DCA is an excellent mechanistic probe for the therapeutic efficiency and cellular 
internalisation of NMOFs,32 while its less problematic side-effects, together with the lower 
cancer cells resistance towards it, compared to other anticancer drugs, make it a potential 
therapeutic candidate if it can be efficiently delivered.  
From the chemical point of view, the lower pKa value (1.96) of dichloroacetic acid means 
considerable amounts can be attached to UiO-66 Zr positions at defect sites during 
synthesis (Scheme 2), even in the presence of other functionalised modulators. Additionally, 
this concept of defect loading of drugs that act as modulators in synthesis could be applied 
to any therapeutic molecule containing carboxylate groups, such as doxorubicin.  
 
Scheme 2. Synthesis of DCA-loaded, surface modified MOFs obtained through coordination 
modulation (CM), click modulation, and postsynthetic exchange (PS). 
Attaching a small molecule with anticancer activity to UiO-66 Zr positions during synthesis, 
creating defective structures, also allows the possibility of introducing a second drug into the 
MOF pores for multimodal treatments. For example, cisplatin prodrugs containing axial DCA 
ligands have been reported to be more effective than cisplatin, and able to overcome 
cisplatin resistance.57 Similarly, DCA is known to enhance the anticancer effect of 5-
fluorouracil (5-FU) and to reduce resistance.60 
DCA@UiO-66, DCA@UiO-66-L1, and DCA@UiO-66-L2 were prepared (SI, Section S7.1) 
and found to be highly crystalline and phase pure, as determined by PXRD, with high DCA 
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content, 15-20% (w/w), measured by both TGA and inductively coupled plasma mass 
spectrometry (ICP-MS) analysis (Table 1). 1H NMR spectroscopy showed incorporation of 
functionalised modulators incorporation (between 3 and 6 mol % compared to bdc) as well 
as DCA. Further characterisation of the samples’ porosity showed that DCA is not stored in 
the pores, but attached to UiO-66 available zirconium positions, inducing defects and 
yielding highly porous nanoparticles of 70-170 nm in size, with BET areas between 1300 
m2g-1 and 1540 m2g-1, higher than unmodulated UiO-66.41 In concordance, TGA profiles 
showed that DCA thermal decomposition occurs at a higher temperature than the one 
reported for the free drug,61 and FT-IR profiles show shifting of the DCA carbonyl vibration 
band as a consequence of DCA coordination to available zirconium positions through its 
carboxylic acid group. During the preparation of this manuscript it was reported that the pKa 
of the modulator also affects the colloidal stability of MOFs, with the authors finding better 
colloidal dispersion for MOFs synthesised using modulators with lower pKa, as a 
consequence of the formation of defects and subsequent modulator incorporation.62 Our own 
DCA-loaded samples were also found by DLS to be essentially monodisperse in water (SI, 
Figure S7.8). 
The use of folic acid or biotin with DCA as a co-modulator was also studied (SI, Scheme S2) 
to successfully introduce both a metabolically active anticancer molecule and more complex 
surface functionalities to UiO-66 structure in only one synthetic step (SI, Section S7.2). As 
with the above DCA@NMOFs, full characterisation of the samples through PXRD, 1H NMR 
spectroscopy, ICP-MS, FT-IR, TGA, SEM and nitrogen adsorption isotherms showed phase 
pure crystalline samples, with high DCA content (around 19% w/w, Table 1), functionalised 
modulator incorporation and appropriate size for drug delivery. The incorporation of both 
DCA and folic acid can also be tuned by changing the ratio of modulators (FA and DCA) 
introduced during synthesis. The samples were named as DCA10@UiO-66-FA0.25 (CM), 
DCA5@UiO-66-FA1 (CM), where the different numbers correlate to the equivalents of 
modulator added during synthesis, and DCA@UiO-66-Biot (CM).  
Covalent attachment of the drug at defect sites throughout the MOF nanoparticle should 
facilitate slow release and the potential to overcome burst release, which can hinder many 
MOF-based DDSs, as well as allow the possibility of loading a second drug into the 
enhanced porosity for combined treatments. Importantly, the attachment of DCA throughout 
the MOF ensures it is not lost on postsynthetic modification. CuAAC covalent modifications 
yielded DCA@UiO-66-L1-PolyLact and DCA@UiO-66-L2-PNIPAM as we previously 
demonstrated for DCA@UiO-66-L1-PEG2000 (SI, Scheme S2), and full characterisation 
showed retention of crystallinity, polymer attachment and significant DCA content (SI, 
Section 7.3). Folic acid, biotin and heparin were also postsynthetically coordinated to 
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DCA@UiO-66 surface, yielding DCA@UiO-66-FA (PS), DCA@UiO-66-Biot (PS) and UiO-
66-Hep (PS) while conserving DCA attachment. The DCA content of all samples, determined 
independently by TGA and ICP-MS, is given in Table 3. 
Table 3. Particle sizes, determined by SEM, and DCA loadings, determined independently by TGA 
and ICP-MS, of the surface modified MOFs. 
Sample 
SEM Particle Size 
(nm) 
DCA 
(TGA, 
% w/w) 
DCA 
(ICP-MS, 
% w/w) 
DCA@UiO-66 77 ± 24 17.0 16.9 
DCA@UiO-66-L1 100 ± 15 15.9 15.5 
DCA@UiO-66-L2 77 ± 11 18.7 18.9 
DCA@UiO-66-L1-PolyLact 138 ± 27 9.0 7.6 
DCA@UiO-66-L2-PNIPAM 159 ± 21 n/aa 3.2 
DCA@UiO-66-FA (PS) 146 ± 38 15.8 13.3 
DCA@UiO-66-Biot (PS) 130 ± 33 15.6 9.4 
DCA@UiO-66-Hep (PS) 133 ± 33 n/aa 5.1 
DCA10@UiO-66-FA0.25 (CM) 158 ± 23 19.6 18.9 
DCA5@UiO-66-FA1 (CM) 91 ± 29 12.1 11.8 
DCA@UiO-66-Biot (CM) 166 ± 22 19.0 20.7 
a
Could not be calculated due to overlapping thermal decomposition events. 
To investigate the consequences of surface coating on the therapeutic efficacy of the 
surface functionalised NMOFs, the cytotoxicity of the materials against three different cell 
lines – HeLa (cervical cancer), MCF-7 (breast carcinoma) and HEK293 (healthy kidney) – 
was analysed by the MTS assay (SI, Section S8). At first, HeLa cell proliferation when 
incubated with the empty surface functionalised NMOFs for 72 h was investigated, finding 
that only UiO-66-L2-PNIPAM was cytotoxic for concentrations above 0.25 mgmL-1, while 
incubation with other coated UiO-66 samples enhanced HeLa cells proliferation with a dose-
response pattern, presumably as a consequence of the incorporation of the NMOFs’ organic 
components into their metabolic cycle (SI, Section S8.1). 
In order to study the therapeutic efficacies of the folate coated NMOFs and assess the 
different methods of surface modification, we incubated HeLa cells with various 
concentrations of DCA@UiO-66-FA (PS), DCA10@UiO-66-FA0.25 (CM) or DCA5@UiO-66-FA1 
(CM) for 72 h. Figure 6 shows the HeLa cell viability for the different NMOFs, normalized 
with an untreated control. We have previously shown that empty UiO-66 is not cytotoxic 
towards HeLa cells,33 and although unfunctionalised DCA@UiO-66 also does not decrease 
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HeLa cell proliferation (128 ± 5% cell viability at a concentration of 1 mgmL-1), likely as a 
consequence of inefficient cytosolic release after clathrin-mediated internalisation, all the 
folate-coated, DCA-loaded MOFs had decreased proliferation to a certain extent in a dose 
responsive manner (Figure 6a). Interestingly, the postsynthetically coated DCA@UiO-66-FA 
(PS) was the least cytotoxic, with 74 ± 4% cell viability at a NMOF concentration of 1 mgmL-
1. Of the two samples prepared through coordination modulation, DCA5@UiO-66-FA1 (CM), 
which has a higher folate content, was the most cytotoxic, with 14 ± 6% of cell proliferation at 
a NMOF concentration of 0.25 mgmL-1 and killing all cells (2 ± 1%) when incubated with 1 
mgmL-1 of NMOF in growth media. DCA10@UiO-66-FA0.25 (CM) started to reduce cell 
proliferation at 0.75 mgmL-1 (85 ± 3%) and only kills 52 ± 5% of cells at 1 mgmL-1, despite 
containing more DCA (~19% w/w) than DCA5@UiO-66-FA1 (CM) (~12% w/w). Clearly the 
mode of external surface attachment of folate is key to therapeutic activity: the most 
cytotoxic folate-coated MOF has the lowest drug content. The enhanced cytotoxicity may be 
due to folate coating enhancing endocytosis efficiency and promoting caveolae-mediated 
endocytosis, which we showed previously enhanced cytotoxicity of PEGylated UiO-66 
loaded with DCA.32 The postsynthetically coated MOF will have the bulk of the folic acid on 
the nanoparticle external surface, while the NMOFs prepared by coordination modulation 
may have folate throughout the nanoparticles in defect sites, enhancing the targeting 
properties even after the onset of degradation. Cytotoxicity of free DCA towards HeLa was 
found to be negligible until cells were incubated with concentrations >4 mgmL-1(SI, Section 
S8.3) confirming that effective delivery of DCA into cells by the DDSs is occurring, with a 
greater than 300 fold enhancement in cytotoxicity compared to the free drug when DCA is 
transported into HeLa cells by DCA5@UiO-66-FA1 (CM). 
Interestingly, DCA@UiO-66-L1-PolyLact produced a similar effect on HeLa cell growth 
regardless of the incubation time, which could be indicative of its significant internalisation by 
energy-independent endocytosis, while empty UiO-66-L1-PolyLact did not show any toxicity. 
Inhibition of cell growth starts to be observed when incubated with 0.75 mgmL-1 of DCA-
loaded MOF for 72 h (85 ± 3% cell viability), while it kills almost all HeLa cells at 1 mgmL-1 
(Figure 6b). Although the empty UiO-66-L2-PNIPAM was already found to be cytotoxic at 
concentrations of 0.5 mgmL-1 and above, DCA loading enhanced its cytotoxic effects, with 
DCA@UiO-66-L2-PNIPAM killing all HeLa cells at the NMOF concentration of 0.25 mgmL-1. 
In contrast to folate coated NMOFs, although heparin coating resulted in enhanced 
endocytosis efficiency and partial uptake by caveolae-mediated endocytosis, no decrease in 
cell proliferation was found when HeLa cells were incubated with DCA@UiO-66-Hep for 72 h 
(Figure 6c). UiO-66-Hep showed undesirable degradation kinetics and colloidal stability 
when compared to UiO-66 precursor samples, and so may not be suitably stable. 
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Additionally, the growth of three different colon cancer cell lines has been reported to be 
stimulated upon heparin addition,63 which might explain why, even if endocytosis efficiency 
and routes are enhanced, no anticancer efficacy is found in this case. In addition, no 
cytotoxicity was observed for DCA@UiO-66-Biot (PS) or DCA@UiO-66-Biot (CM) over 72 h 
of incubation, in concordance with the fact that endocytosis studies showed that cal@UiO-
66-Biot (PS) is not efficiently taken up by HeLa cells. 
 
 
Figure 6. Cytotoxicity of UiO-66 samples as measured by MTS assay after 72 h incubation with the 
respective cells. a) HeLa cytotoxicity of the DCA-loaded, folic acid modified MOFs to assess the effect 
of surface functionalisation method. b) HeLa cytotoxicity of the “click modulated” MOFs, with and 
without DCA cargo. c) HeLa cytotoxicity of empty and DCA-loaded heparin and biotin modified 
samples. Cytotoxicities of the best DCA-loaded MOF candidates, as assessed by the HeLa 
experiments, for d) MCF-7 cells, and e) HEK293 cells (the key in part d applies to both). f) 
Comparison of cytotoxicity of DCA5@UiO-66-FA1 (CM) against the three cell-lines, indicating selective 
toxicity towards cancer cell lines only. 
Because of these encouraging results, we further investigated the in vitro anticancer 
selectivity of the most cytotoxic candidates (DCA5@UiO-66-FA1 (CM), DCA@UiO-66-L1-
PolyLact and UiO-66-L2-PNIPAM), by MTS assay (72 h incubation) against a breast cancer 
cell line (MCF-7, standing for Michigan Cancer Foundation-7), and a healthy kidney cell line 
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(HEK293, standing for human embryonic kidney cells 293). We compared the cell viability 
with the DCA-loaded, unfunctionalised NMOF, DCA@UiO-66 (SI, Section S8.2).64 
We investigated the effect of the unfunctionalised DCA@UiO-66, which has the highest DCA 
content, against MCF-7 (Figure 6d) and HEK293 (Figure 6e) cells, finding no negative 
effects on their viability, with 136 ± 4% and 212 ± 20% cell proliferation after 72 h of 
incubation with a solution of 1 mgml-1 of MOF compared to untreated controls. After 72 h of 
incubation, MCF-7 cell proliferation was drastically reduced when treated with DCA5@UiO-
66-FA1 (CM) (Figure 6d). The dose-responsive curve showed a similar trend to the HeLa 
experiment, although with slightly lower efficacy; 71 ± 8% cell viability at a concentration of 
0.5 mgmL-1 and 35 ± 8% for a concentration of 1 mgmL-1. More importantly, after 72 h of 
incubation with HEK293 cells, proliferation was not reduced in the presence of DCA5@UiO-
66-FA1 (CM) at any concentration, with 107 ± 5% cell viability at the NMOF concentration of 
1 mgmL-1 (Figure 6e). These results suggest folate induces cancer cell-targeting, as HeLa 
cells have a higher FR overexpression than MCF-7,65 and thus therapeutic efficacy in HeLa 
is more pronounced. On the other hand, HEK293 has been reported to have normal levels of 
expression of the FR,66 and thus no effect is observed on their cell proliferation possibly as a 
consequence of poor internalisation and/or a lack of metabolic effect of DCA on healthy 
cells. It is also important to consider that free dichloroacetate was not cytotoxic to either 
MCF-7 or HEK293 cells at the concentrations delivered by the NMOFs (SI, Section S8.3), 
confirming the efficient delivery of DCA into the cells by the MOF DDSs.  
Interestingly, DCA@UiO-66-L1-PolyLact and DCA@UiO-66-L2-PNIPAM were less cytotoxic 
towards MCF-7 and HEK293 than HeLa cells (Figures 6d and 6e). Incubation with 
DCA@UiO-66-L1-PolyLact for 72 h resulted in similar cytotoxicity values for both cell lines at 
higher concentrations; 82 ± 8% (MCF-7) and 85 ± 16% (HEK293) cell viability at 1 mgml-1. 
DCA@UiO-66-L2-PNIPAM showed cytotoxicity for both, but more pronounced for MCF-7 
(32 ± 8% viability) than for HEK293 (78 ± 14% viability) at 1 mgmL-1. While the polymer 
coated, DCA loaded samples do show cytotoxicity towards MCF-7, the residual cytotoxicity 
towards HEK293 is a concern.  
Our previous work with PEG-coated UiO-66 showed excellent cytotoxicity towards HeLa 
when loaded with DCA, and so the effect of polymer coating was further examined by 
determining the cytotoxicity of DCA@UiO-66-L1 and DCA@UiO-66-L1-PEG2000 towards 
MCF-7 and HEK293 cells. While DCA@UiO-66-L1 does not affect MCF-7 cell proliferation 
negatively, DCA@UiO-66-L1-PEG2000 induced some cytotoxicity with a 32 ± 3% cell 
proliferation during the same experiment, similar to the cell viability reported for HeLa cells 
(50 ± 3%) at the same concentration.32 However, some unwanted cytotoxicity of DCA@UiO-
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66-L1-PEG2000 was observed against HEK293 (42 ± 6% viability) at the highest 
concentration of 1 mgml-1, in contrast to DCA@UiO-66-L1.  
In vitro Immune Response to DCA-Loaded NMOFs 
The immune response toward exogenous materials plays a crucial role in any treatment 
efficacy; DDSs will not be efficient if they are cleared out of the blood stream by 
macrophages, or if they stimulate/suppress immune response or induce tissue damage 2. 
Cytotoxicity, uptake efficiency and reactive oxygen species (ROS) production by immune 
cells such as macrophages or lymphocytes are of great importance when considering the 
efficiency of a DDS, but, to the best of our knowledge, only few studies have assessed these 
issues with NMOFs to date.14,23,67,68 Importantly, it can provide further insights into possible 
treatment efficiency without resorting to early stage animal testing. 
The cytotoxicity of empty and DCA-loaded candidate NMOFs towards both macrophages 
(J774 cell line) and a pool of peripheral blood lymphocytes (PBLs) isolated from the blood of 
three human donors were investigated (SI, Section S9). It has been reported that DCA does 
not affect the mitochondrial functions of healthy cells,55 and therefore should not induce any 
cytotoxicity. Internalisation efficiency of the NMOFs by macrophage cells was investigated 
by incubation of J774 cells with 0.25 mgmL-1 of calcein loaded NMOFs, followed by analysis 
of intracellular fluorescence by FACS (SI, Section S9.1). Normalised cell fluorescence 
showed that only PEGylation decreased macrophage uptake, to levels of 80 ± 4% compared 
to UiO-66-L1. cal@UiO-66-FA (PS) was the most efficiently internalised NMOF, with a 189 ± 
15% – expected, as activated macrophages are known to overexpress the folate receptor – 
followed by cal@UiO-66-L2-PNIPAM with a 176 ± 9% cell internalisation and cal@UiO-66-
L1-PolyLact with a 155 ± 7% macrophage uptake efficiency.  
MTT assays were carried out to assess the viability of J774 macrophage cells (Figure 7a) 
after incubation with several concentrations of surface modified UiO-66 in media for 48 h (SI, 
Section S9.2). No cytotoxicity was observed when incubating J774 cells with either UiO-66-
FA (CM) or DCA5@UiO-66-FA1 (CM), despite the fact that, in contrast to the folate receptor 
negative HEK293 healthy cell line, activated macrophages overexpress the folate receptor.69 
In fact, cell proliferation was slightly enhanced (128 ± 10% and 142 ± 11%, respectively) at a 
NMOF concentration of 0.5 mgmL-1. Similar results were obtained when a pool of PBLs was 
incubated with folate-coated NMOFs for 72 h, obtaining enhanced, dose-responsive cell 
proliferation by MTT assay for two independent experiments (one is plotted in Figure 7b, 
comparison available in SI) which showed similar trends. Viabilities of 295 ± 24% and 199 ± 
34% for empty UiO-66-FA (CM) and 252 ± 28% and 146 ± 18% for DCA5@UiO-66-FA1 (CM) 
were found at 0.5 mgmL-1 incubation.  
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Figure 7. Cytotoxicity of empty and DCA-loaded UiO-66 samples against a) J774 macrophage cells 
and b) a pool of peripheral blood lymphocytes from three human donors. The key for part a) also 
applies in part b). c) Reactive oxygen species generation by J774 macrophage cells in the presence 
of empty and DCA-loaded UiO-66 samples. 
Cytotoxicity assays showed that UiO-66-L1-PolyLact and UiO-66-L2-PNIPAM were well 
tolerated by J774 macrophages (both having 89 ± 1% cell viability at 0.5 mgmL-1), although 
DCA@UiO-66-L1-PolyLact and DCA@UiO-66-L2-PNIPAM killed almost all cells, despite the 
reports that DCA does not affect healthy cells. Cell viability values of 27 ± 2% and 4 ± 4%, 
respectively, induced by incubation with 0.5 mgmL-1 NMOF (Figure 7a), suggest that the 
surface functionalities, together with DCA, might have some synergistic effect on metabolic 
activity. Similar results were observed for PBL cell proliferation (Figure 7b), for which the 
empty NMOFs, UiO-66-L1-PolyLact and UiO-66-L2-PNIPAM, did not induce cell death at 0.5 
mgmL-1 (164 ± 59% and 134 ± 14% viability for the former; 138 ± 12% and 101 ± 41% 
viability for the latter), while incubation with DCA@UiO-66-L1-PolyLact and DCA@UiO-66-
L2-PNIPAM under the same conditions reduced cell viability to values of 45 ± 11% and 17 ± 
5% for the former, and 7 ± 2% and 3 ± 4% for the latter. These are major issues that may 
preclude the use of the polymer-coated samples in vivo. 
The effect of the chemical constitution of the polymer chain was studied further by incubating 
J774 macrophages with our previously reported UiO-66-L1-PEG2000 and DCA@UiO-66-L1-
PEG2000 materials, which decreased their cell proliferation to levels of 54 ± 1% and 70 ± 
2%, respectively, at 0.5 mgmL-1 (Figure 7a). In contrast, UiO-66-L1-PEG2000 and 
DCA@UiO-66-L1-PEG2000 induced PBL cell proliferation from a single pool to levels of 116 
± 12% and 128 ± 21% compared to untreated cells at a concentration of 0.5 mgmL-1 (Figure 
7b). Whilst the response of the J774 cells and the HEK293 cells to DCA@UiO-66-L1-
PEG2000 could be problematic, the selectivity of the cytotoxicity of folate targeted, DCA 
loaded, DCA5@UiO-66-FA1 (CM) nanoparticles is very promising, killing almost all cancer 
cells whilst not negatively affecting the proliferation of healthy cells. 
25 
 
Reactive oxygen species (ROS) production was investigated to gain insights into the 
cytotoxic effects of the NMOFs and to assess induction of oxidative stress.70 J774 
macrophage cells and PBLs were incubated with different doses of the NMOFs over 2 h, 
followed by incubation with the intracellular fluorescent probe 2',7'-dichlorodihydrofluorescein 
diacetate (H2DC-FDA) in order to track ROS production by flow cytometry (SI, Section 
S9.3). DCA@UiO-66-L2-PNIPAM induced the highest ROS production in the J774 
macrophages (Figure 7c), with a 5.5 fold increase at a NMOF concentration of 0.5 mg mL-1 a 
possible reason for the significant cytotoxicity, while the non-cytotoxic empty UiO-66-L2-
PNIPAM only induced a 1.4 fold increase in ROS production at the same concentration. 
Whilst empty UiO-66-L1-PolyLact did not induce significant cytotoxicity in the J774 cell lines, 
higher ROS production was found when incubating macrophages with the empty sample 
(3.2 fold increase) compared to DCA@UiO-66-L1-PolyLact (1.9 fold increase), which is more 
cytotoxic. Similarly, incubating J774 macrophages with UiO-66-L1-PEG2000 induced a 
slightly higher ROS production (2 fold increase) than incubation with DCA@UiO-66-L1-
PEG2000 (1.5 fold increase) for the same concentration. UiO-66-FA (CM) did not induce 
significant ROS production, with a 1.2 fold increase when incubating macrophages with a 0.5 
mgmL-1 concentration of NMOF, while DCA5@UiO-66-FA1 (CM) did induce ROS production 
with a 2.8 fold increase, although MTT assays showed cell proliferation was enhanced in all 
cases, suggesting that ROS production is not a major source of cytotoxicity for these 
particular MOFs. ROS production in PBLs was also monitored (SI, Section S9.3) with no 
discernible trends, although DCA5@UiO-66-FA1 was again well tolerated. These results 
suggest that while higher concentrations MOFs can induce some ROS production, it does 
not seem to result in cytotoxicity towards these healthy cells. It is also important to note that 
concentrations of DCA-loaded NMOFs lower than 0.5 mgmL-1 did not induce considerable 
ROS production, despite being therapeutically active towards cancer cell lines. 
CONCLUSIONS 
In conclusion, we have assessed a number of different functionalities, as well as different 
surface modification protocols – coordination modulation, postsynthetic exchange, and 
covalent click modulation – for the surface functionalisation of UiO-66 nanoparticles for use 
in drug delivery. The use of carboxylate-containing drug molecules as modulators for 
synthesis of UiO-66 nanoparticles, in this study the anticancer metabolic target 
dichloroacetic acid, has been shown to be an efficient methodology to ensure high cargo 
loading at defect sites in one-pot syntheses that are also compatible with all the surface 
modification protocols. DCA modulation in particular generates colloidally-stable 
nanoparticles with high DCA-loading values that are amenable to further functionalisation 
without compromising porosity. 
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In nearly all cases, surface functionalisation enhances properties such as colloidal 
dispersion and stability towards phosphate-induced degradation compared to bare UiO-66. 
Internalisation by HeLa cells is enhanced – apart from biotin-coated samples – and certain 
surface coatings tune internalisation pathways to more desirable uptake routes, such as 
caveolae-mediated endocytosis, which may allow MOFs to escape the early endosome and 
result in increased cytosolic cargo release. Building on our preliminary results that show 
DCA@UiO-66-PEG2000 has enhanced cytotoxicity for HeLa as a consequence of its more 
efficient caveolae-mediated endocytosis, extensive in vitro studies of DCA-loaded materials 
have shown that folic acid coated MOFs exhibit selective cytotoxicity towards HeLa (cervical) 
and MCF-7 (breast cancer) cells, without adversely affecting proliferation of healthy kidney 
(HEK293), macrophage (J774) and PBL cells, possibly due to the over expression of the 
folate receptor on the surfaces of cancer cells and a preference for desirable caveolae-
mediated endocytosis. The method of folic acid coating is vital – incorporation of folic acid 
and DCA in a one-pot, modulated synthesis produced significantly more active MOFs than 
postsynthetically coating MOFs with folic acid. Hence, the therapeutic efficiency of free DCA 
was drastically improved, with a >300 fold increase in selective cytotoxicity observed when 
loaded into DCA5@UiO-66-FA1 (CM), while uncoated DCA@UiO-66 did not produce any 
negative effect on the various cell lines.  
The polymer-coated, DCA loaded MOFs prepared by click modulation also showed 
therapeutic potential, decreasing proliferation of the cancerous cell lines, but each had 
drawbacks. Both DCA@UiO-66-L1-PolyLact and DCA@UiO-66-L2-PNIPAM induced death 
in J774 macrophage cells and human lymphocytes – key components of the immune system 
– with the latter stimulating significant ROS production in J774 cells. While DCA@UiO-66-
L1-PEG2000 was tolerated well by the immune system cells, as would be expected, it 
induced some cytotoxicity in healthy kidney cells at high concentrations, suggesting in vivo 
accumulation in healthy tissue might induce damage. 
These results demonstrate the power of surface functionalisation and importance of cell 
internalisation pathways in the application of MOFs for drug delivery. The potential of 
DCA5@UiO-66-FA1 for use as a selective anticancer DDS for in vivo localised treatment is 
apparent, particularly given the use of the metabolic probe DCA as a modulator during 
synthesis resulting in a drug-loaded nanoparticle that is still porous and could be loaded with 
a second drug for synergistic multimodal therapy,60 which we are currently investigating. The 
work also highlights the broad in vitro experimental toolkit available to provide information on 
cellular uptake, endocytosis mechanisms, immune response and cytotoxicity prior to any in 
vivo treatment, thus reducing the need for early stage animal testing and acting according to 
the three Rs: reduction, refinement and replacement.  
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